ID ORF3B_SARS2 Reviewed; 22 AA. AC P0DTF1; DT 10-FEB-2021, integrated into UniProtKB/Swiss-Prot. DT 10-FEB-2021, sequence version 1. DT 02-OCT-2024, entry version 13. DE RecName: Full=Putative ORF3b protein {ECO:0000305|PubMed:32854725}; DE Short=ORF3b; OS Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2). OC Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes; OC Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae; OC Betacoronavirus; Sarbecovirus; OC Severe acute respiratory syndrome coronavirus. OX NCBI_TaxID=2697049; OH NCBI_TaxID=9606; Homo sapiens (Human). RN [1] RP NUCLEOTIDE SEQUENCE [GENOMIC RNA]. RX PubMed=32015508; DOI=10.1038/s41586-020-2008-3; RA Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W., RA Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y., RA Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.; RT "A new coronavirus associated with human respiratory disease in China."; RL Nature 579:265-269(2020). RN [2] RP REVIEW. RX PubMed=32854725; DOI=10.1186/s12985-020-01402-1; RA Michel C.J., Mayer C., Poch O., Thompson J.D.; RT "Characterization of accessory genes in coronavirus genomes."; RL Virol. J. 17:131-131(2020). RN [3] RP MISCELLANEOUS. RX PubMed=32807944; DOI=10.1038/s41590-020-0773-7; RA Hachim A., Kavian N., Cohen C.A., Chin A.W.H., Chu D.K.W., Mok C.K.P., RA Tsang O.T.Y., Yeung Y.C., Perera R.A.P.M., Poon L.L.M., Peiris J.S.M., RA Valkenburg S.A.; RT "ORF8 and ORF3b antibodies are accurate serological markers of early and RT late SARS-CoV-2 infection."; RL Nat. Immunol. 21:1293-1301(2020). RN [4] RP FUNCTION. RX PubMed=32941788; DOI=10.1016/j.celrep.2020.108185; RG USFQ-COVID19 Consortium; RA Konno Y., Kimura I., Uriu K., Fukushi M., Irie T., Koyanagi Y., Sauter D., RA Gifford R.J., Nakagawa S., Sato K.; RT "SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is RT Increased by a Naturally Occurring Elongation Variant."; RL Cell Rep. 32:108185-108185(2020). RN [5] RP GENOME REANNOTATION. RX PubMed=33976134; DOI=10.1038/s41467-021-22905-7; RA Jungreis I., Sealfon R., Kellis M.; RT "SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 RT Sarbecovirus genomes."; RL Nat. Commun. 12:2642-2642(2021). CC -!- FUNCTION: Acts as an interferon antagonist when expressed ex vivo. CC {ECO:0000269|PubMed:32941788}. CC -!- INTERACTION: CC P0DTF1; P52954: LBX1; Xeno; NbExp=3; IntAct=EBI-26953451, EBI-20141748; CC P0DTF1; Q9GZY8: MFF; Xeno; NbExp=3; IntAct=EBI-26953451, EBI-11420856; CC -!- MISCELLANEOUS: SARS-CoV-2 ORF3b is homologous to SARS-CoV ORF3b, CC although the proposed protein is much shorter due to the presence of CC premature stop codons (Probable). Elicits strong specific antibody CC response (PubMed:32807944). {ECO:0000269|PubMed:32807944, CC ECO:0000305|PubMed:32854725}. CC -!- CAUTION: Product of a dubious CDS prediction. CC {ECO:0000303|PubMed:33976134}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; MN908947; -; NOT_ANNOTATED_CDS; Genomic_RNA. DR IntAct; P0DTF1; 36. DR MINT; P0DTF1; -. DR PRO; PR:P0DTF1; -. DR Proteomes; UP000464024; Genome. DR GO; GO:0052170; P:symbiont-mediated suppression of host innate immune response; IEA:UniProtKB-KW. DR GO; GO:0019049; P:virus-mediated perturbation of host defense response; IEA:UniProtKB-KW. PE 5: Uncertain; KW Host-virus interaction; Inhibition of host innate immune response by virus; KW Interferon antiviral system evasion; Reference proteome; KW Viral immunoevasion. FT CHAIN 1..22 FT /note="Putative ORF3b protein" FT /id="PRO_0000452089" SQ SEQUENCE 22 AA; 2457 MW; 53D80549C8F78A22 CRC64; MMPTIFFAGI LIVTTIVYLT IV //